Compare Gilead Sciences, Inc. (GILD) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Block Inc — how do they compare? Gilead Sciences, Inc. trades at $133.33 (market cap $163.51B), while Block Inc trades at $81.75 (market cap $48.69B). The key difference: Gilead Sciences, Inc. is far larger — about 3.4× Block Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| GILD | XYZ | |
|---|---|---|
Market Cap | $163.51B | $48.69B |
Sector | Health | Technology |
52-Week High | $155.80 | $81.81 |
52-Week Low | $108.22 | $49.04 |
Enterprise Value | $178.05B | $43.56B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Block (XYZ) trades at $79.99, up 1.61% on the day, with a bullish technical signal from moving averages. The stock shows mixed fundamentals with a high P/E of 63.91 offset by recent earnings beats and strong analyst consensus. Recent news highlights growth in Cash App and Square, tempered by a $45 million regulatory settlement and insider selling activity.
The outlook is cautiously optimistic, supported by analyst upgrades and a $88.53 price target. Key opportunities include AI-driven product expansion and accelerating mobile payment trends. Risks include elevated valuation, rising credit losses, regulatory scrutiny, and inconsistent cash flow generation, which could pressure the stock near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
